Advertisement

HindustanTimes Thu,18 Sep 2014

Bayer loses plea against cheap Indian cancer drug

AP  New Delhi, March 05, 2013
First Published: 11:54 IST(5/3/2013) | Last Updated: 12:04 IST(5/3/2013)

India's patent appeals office has rejected international drug maker Bayer AG's plea to stop an Indian company from manufacturing a cheaper generic version of a patented cancer drug.

Advertisement

The ruling passed on Monday is being hailed as an important precedent for getting inexpensive life-saving drugs to the poor.

The German company had filed an appeal against the Indian patents office's decision last year to grant a compulsory license to local drug manufacturer Natco Pharma to produce a generic version of its kidney and liver cancer treatment Nexavar.

Bayer sells a one month supply of the drug for about $5,600. Natco's version would cost Indian patients $175 a month.


Advertisement
more from New Delhi

Badaun case: Eye-witness flunks lie-detector test

In a fresh twist, the main eyewitness in the case related to the alleged rape and murder of two minor girls in Badaun in May, Nazru, has allegedly flunked the polygraph test conducted on him by the Central Bureau of Investigation (CBI).

Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved